Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Reiterated by HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $41.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 94.68% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. Scotiabank cut shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and cut their price target for the stock from $36.00 to $23.00 in a report on Wednesday, January 31st. JPMorgan Chase & Co. upped their price target on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Finally, StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, January 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $34.42.

Syndax Pharmaceuticals Trading Up 2.4 %

SNDX opened at $21.06 on Friday. The company has a fifty day moving average price of $22.67 and a two-hundred day moving average price of $19.61. The company has a market cap of $1.79 billion, a P/E ratio of -7.11 and a beta of 1.03. Syndax Pharmaceuticals has a 1-year low of $11.22 and a 1-year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, February 27th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.01). During the same period in the prior year, the company earned ($0.62) EPS. On average, research analysts forecast that Syndax Pharmaceuticals will post -3.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. CWM LLC increased its holdings in shares of Syndax Pharmaceuticals by 415.3% in the 4th quarter. CWM LLC now owns 1,685 shares of the company’s stock worth $36,000 after buying an additional 1,358 shares during the last quarter. MeadowBrook Investment Advisors LLC purchased a new stake in Syndax Pharmaceuticals during the 4th quarter valued at $37,000. China Universal Asset Management Co. Ltd. boosted its position in Syndax Pharmaceuticals by 97.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,782 shares of the company’s stock valued at $26,000 after buying an additional 880 shares during the period. Quadrant Capital Group LLC lifted its position in shares of Syndax Pharmaceuticals by 158.3% in the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock worth $53,000 after purchasing an additional 1,496 shares during the period. Finally, Signaturefd LLC lifted its position in shares of Syndax Pharmaceuticals by 2,874.6% in the 4th quarter. Signaturefd LLC now owns 3,748 shares of the company’s stock worth $81,000 after purchasing an additional 3,622 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).